Novel insights into the regulation of postprandial lipemia by glucagon-like peptides: Significance for diabetes

Diabetes

Volumn 62, Issue 2, 2013, Pages 336-338

  Watts, Gerald F ^a   Chan, Dick C ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B48; CHYLOMICRON; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2;

ANIMAL EXPERIMENT; DIABETES MELLITUS; HYPERLIPIDEMIA; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; MALE; NONHUMAN; NOTE; POSTPRANDIAL STATE; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 84873040246     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1098     Document Type: Note

References (20)

1. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142:521-527
2. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-835
3. Farr S, Adeli K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr Opin Lipidol 2012;23:56-61
4. Drucker DJ. Glucagon-like peptide 2. J Clin Endocrinol Metab 2001;86:1759-1764
5. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010;53:552-561
6. Qin X, Shen H, Liu M, et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005;288:G943-G949
7. Hsieh J, Longuet C, Maida A, et al. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastro-enterology 2009;137:997-1005, 1005, e1-e4
8. Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006;130:44-54
9. Hein GJ, Baker C, Hsieh J, Farr S, Adeli K. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes 2013;62:373-381
10. Federico LM, Naples M, Taylor D, Adeli K. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes 2006;55:1316-1326
11. Barrett PHR, Chan DC, Watts GF. Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans. J Lipid Res 2006;47:1607-1619
12. Xiao C, Hsieh J, Adeli K, Lewis GF. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am J Physiol Endocrinol Metab 2011;301:E429-E446
13. Levy E, Sinnett D, Thibault L, Nguyen TD, Delvin E, Ménard D. Insulin modulation of newly synthesized apolipoproteins B-100 and B-48 in human fetal intestine: gene expression and mRNA editing are not involved. FEBS Lett 1996;393:253-258
14. p38. Diabetes 2003;52:1073-1080
15. Maljaars PW, Peters HP, Mela DJ, Masclee AA. Ileal brake: a sensible food target for appetite control. A review. Physiol Behav 2008;95:271-281
16. Pang J, Chan DC, Barrett PHR, Watts GF. Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects. Curr Opin Lipidol 2012;23: 303-309
17. Duez H, Pavlic M, Lewis GF. Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. Atheroscler Suppl 2008;9:33-38
18. Jeppesen PB. Glucagon-like peptide-2: update of the recent clinical trials. Gastroenterology 2006;130(Suppl. 1):S127-S131
19. Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011;97:350-356
20. Sivertsen J, Rosenmeier J, Holst JJ, Vilsbøll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012;9:209-222